Related Experiment Video

Updated: Oct 17, 2026

Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus
08:16

Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus

Published on: June 17, 2015

Intracellular biology of Alzheimer's disease amyloid beta peptide

T Hartmann1

  • 1Center for Molecular Biology (ZMBH), University of Heidelberg, Germany. tobias.hartmann@mail.zmbh.uni-heidelberg.de

European Archives of Psychiatry and Clinical Neuroscience
|February 1, 2000
PubMed

Insights

Alzheimer

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Biochemistry

Background:

  • Alzheimer's disease (AD) pathogenesis is strongly linked to the overproduction of beta-amyloid 42 (Abeta42).
  • Abeta42 is now understood to be released during normal cellular metabolism of the Alzheimer amyloid precursor protein, not solely from a pathogenic event.
  • Recent findings indicate Abeta42 is produced intracellularly, revealing a significant cellular pathway for its generation.

Purpose of the Study:

  • To investigate the implications of intracellular Abeta42 production.
  • To explore the potential role of intracellular Abeta production in AD pathogenesis.
  • To understand the differences between secretory and intracellular Abeta production.

Main Methods:

  • Analysis of cellular metabolism pathways.
  • Investigation of Abeta42 production mechanisms.
  • Comparative studies of secretory versus intracellular Abeta release.

Main Results:

  • Abeta42 is produced intracellularly through a recognized cellular pathway.
  • Intracellular Abeta production is not limited to specific cell lines but represents an important pathway.
  • Differences in Abeta production (secretory vs. intracellular) may explain brain specificity and cellular mechanisms in AD.

Conclusions:

  • Intracellular Abeta42 production is a key pathway in cellular metabolism.
  • Understanding intracellular Abeta production is crucial for elucidating AD pathogenesis.
  • Further research into the distinctions between secretory and intracellular Abeta pathways may unlock new therapeutic targets for Alzheimer's disease.

More Related Videos

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP07:55

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

Published on: October 17, 2015

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...